L’Oréal is reportedly in exclusive acquisition talks with UK-based skincare brand Medik8, in a move that would expand the French cosmetics giant’s presence in the fast-growing dermocosmetics market.

According to industry insiders cited by WWD, L’Oréal has emerged as the likely buyer of Medik8 following strong interest from several parties. The brand is currently backed by UK private equity firm Inflexion. Neither L’Oréal nor Medik8 has issued an official statement.

The potential deal aligns with L’Oréal’s ongoing strategy to deepen its offering in science-led skincare. Medik8 would join a portfolio that already includes high-performance skincare brands such as CeraVe, La Roche-Posay, and SkinCeuticals.

Founded in 2009, Medik8 has gained recognition for its results-driven approach to skincare, leveraging scientific innovation and high-quality ingredients to address skin ageing and related concerns. Its product line ranges from vitamin C serums to retinol-based treatments, developed to deliver visible results while prioritising skin health and sustainability.

If finalised, the deal would mark another successful exit for Inflexion in the beauty and wellness space, adding to a growing list of private equity-backed skincare transactions as strategic buyers continue to seek access to clinically backed, premium brands.

Source: The Industry Beauty